German drug and development company Evotec has entered into a technology development partnership with Novo Nordisk to support clinical and commercial manufacturing of stem cell-based therapies, the company said on Thursday.

Evotec SE (NASDAQ:EVO) entered a technology development partnership with Novo Nordisk A/S (NYSE:NVO) in cell therapy. Evotec and Novo Nordisk have significant expertise and a strategic focus on supporting stem cell-based therapies.

While the companies did not reveal the financial details of the deal, Novo Nordisk will provide funding for two Evotec sites in Germany and Italy to support the development of next-generation cell therapies.

Novo Nordisk will provide funding for technology development activities at Evotec to support clinical and commercial manufacturing of stem cell-based therapies HAMBURG, GERMANY / ACCESSWIRE / September 26,

Evotec has joined forces with Novo Nordisk to advance the clinical and commercial manufacturing of stem cell-based therapies.

Evotec has entered a partnership with Novo Nordisk to develop next-generation off-the-shelf cell therapy technologies. Novo Nordisk will fund R&D at Evotec’s sites in Germany and Italy, with an option for exclusive rights to use the results in a specific therapeutic area.